ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE (ADOPT-PRESTAGE)

  • STATUS
    Recruiting
  • End date
    Mar 3, 2024
  • participants needed
    139
  • sponsor
    Hospices Civils de Lyon
Updated on 3 June 2022
cancer treatment
primary cancer

Summary

As the proportion of oral anticancer treatments is continuously increasing, adherence appears as a major issue for patients' outcomes. Poor adherence affects particularly geriatric patients due among others to polypharmacy or cognitive impairment. Thus, the need for educational programs in this population has been regularly emphasized.

PRESTAGE educational program was built after an external and internal analysis of educational needs in elderly patients treated with oral cancer treatments. It implicates a multidisciplinary educational team (nurses, physicians, pharmacists, psychologists, physiologists, social workers...). Six educational workshops were designed with the following endpoints: disease and treatment understanding, treatment management, nutrition and psychological as well as physical well being.

ADOPT-PRESTAGE is a clinical, prospective, interventional, open-label, multicenter, randomized, controlled trial designed to evaluate the impact of PRESTAGE program. It is, to the investigators' knowledge, the first randomized controlled trial evaluating the acceptability and impact (adherence, clinical benefit) of an educational program in an elderly cancer population. The primary endpoint of this trial will be to evaluate adherence using an indirect objective adherence measure: the Medication Event Monitoring System (MEMS). Secondary endpoints include quality of life and evaluation of changes in patients' behaviors.

Details
Condition Cancer, Oral Anticancer Drugs
Treatment PRESTAGE
Clinical Study IdentifierNCT03296150
SponsorHospices Civils de Lyon
Last Modified on3 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients older than 70 years
For which oral anticancer therapy has been initiated within the previous 45 days or will be started within 45 days
For any type of cancer, solid or hematologic, any stage
Estimated life expectancy> 6 months
Affiliation to social security or equivalent
Patients who can answer questionnaires and protocol evaluations
Informed consent signed by patients
Domiciled within 50 km around the investigating center

Exclusion Criteria

For patients with breast cancer, exclusive treatment with hormone therapy
First-generation Hormone Therapy in Prostate Cancer
Patient not available for regular follow-up whatever the cause (geographic, family, social, psychological)
Any serious condition, ie serious physical or mental, leading to a disability permanent and likely to prevent the proper course of treatment
Patient deprived of liberty or under guardianship
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note